PAVmed Inc PAVM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PAVM is a good fit for your portfolio.
News
-
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
-
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
-
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
-
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
-
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
-
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
-
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
Trading Information
- Previous Close Price
- $1.99
- Day Range
- $1.84–1.97
- 52-Week Range
- $1.63–7.83
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $16.97 Mil
- Volume/Avg
- 20,487 / 63,405
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.72
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 124
- Website
- https://www.pavmed.com
Valuation
|
Metric
|
PAVM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 5.72 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PAVM
|
|---|---|
Quick Ratio | 0.36 |
Current Ratio | 0.45 |
Interest Coverage | −134.43 |
Quick Ratio
PAVM
Profitability
|
Metric
|
PAVM
|
|---|---|
Return on Assets (Normalized) | −118.76% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −137.50% |
Return on Assets
PAVM
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Xrsphgbsr | Zfgbkg | $182.7 Bil | |
SYK
| Stryker Corp | Fcckqtdyr | Stqn | $124.6 Bil | |
MDT
| Medtronic PLC | Tkrdbvhw | Cwpvqj | $105.2 Bil | |
BSX
| Boston Scientific Corp | Rvcyknf | Hmxbf | $99.0 Bil | |
DXCM
| DexCom Inc | Wjqnymfrkz | Dkx | $51.8 Bil | |
EW
| Edwards Lifesciences Corp | Blyqrhqyc | Hnwpln | $51.7 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Twtkbsxvl | Sbzms | $24.5 Bil | |
ALGN
| Align Technology Inc | Dncjhnkl | Nsxjtjz | $22.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Jdlswbvf | Nsflb | $18.3 Bil | |
PODD
| Insulet Corp | Zvcfwbsx | Vkccvt | $11.6 Bil |